Ann: MSB Japan Strategy Highlighted At Business Council Meeting-MSB.AX, page-13

History of MSB announcements and effects on share price since the withdrawal of Teva:

09/08/2016: Mesoblast P2 Results Show Dose-Related Improvements In RA
Share price went from $1.135 to $1.925 in 7 days before starting to drop again.

17/08/2016: MSB Strengthens US Patent Portfolio For Rheumatic Diseases
Share price went from $1.505 to $1.655 in 1 day before starting to drop again.

25/08/2016: Preliminary Final Report (Including Appendix 4E)
No noticeable effect on share price

01/09/2016: Mesoblast Appoints Bill Burns As Vice Chairman
Share price went from $1.34 to $1.41 (intraday) in 1 day before closing only $0.015 higher at $1.355.

02/09/2016: S&P DJ Indices Announces September Quarterly Rebalance
Share price went from $1.355 to $1.105 in the next one month and languishes there

06/10/2016: Mesoblast Phase 2 Diabetic Kidney Disease Results Published
Share price went from $1.115 to $1.28 in 1 day before going back down to $1.155

12/10/2016: MSB Japan Strategy Highlighted At Business Council Meeting
Share price went from $1.155 to an intra-day high of $1.17 and now trades at $1.14

---

I can't help but noticing an obvious pattern here:

The pop in the share price that typically follows MSB's recent announcements is getting smaller and smaller and duration of the rally also gets shorter and shorter.

This effect is probably caused by overly eager initial buying by some which is then followed by the realisation that there is nothing substantially new in the announcements.

---

Looking at MSB's recent behaviour, a common quote comes to mind:

Better to Remain Silent and Be Thought a Fool than to Speak and Remove All Doubt

In MSB's case, it should be adjusted to:

Better to Remain Silent and Be Thought in Financial Trouble than to Make Announcements and Remove All Doubt

---